Bay Rivers Group Lowers Stock Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Bay Rivers Group lowered its position in iShares Biotechnology ETF (NASDAQ:IBBFree Report) by 3.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,365 shares of the financial services provider’s stock after selling 84 shares during the period. Bay Rivers Group’s holdings in iShares Biotechnology ETF were worth $313,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. PVG Asset Management Corp bought a new position in shares of iShares Biotechnology ETF in the second quarter worth about $415,000. Huntington National Bank lifted its holdings in iShares Biotechnology ETF by 17.9% in the 3rd quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock worth $153,000 after purchasing an additional 160 shares in the last quarter. National Bank of Canada FI boosted its stake in iShares Biotechnology ETF by 5.9% in the 3rd quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock worth $600,000 after purchasing an additional 229 shares during the period. First Financial Bank Trust Division purchased a new stake in iShares Biotechnology ETF during the 3rd quarter valued at approximately $204,000. Finally, Thrive Wealth Management LLC bought a new stake in shares of iShares Biotechnology ETF during the third quarter valued at approximately $445,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ:IBB opened at $138.37 on Tuesday. The firm has a fifty day moving average price of $136.15 and a 200 day moving average price of $141.77. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The business also recently disclosed a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were issued a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Stories

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBBFree Report).

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.